IFC Advisory is delighted to be working with Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) Midatech is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies, all of which are in the clinic.
Client Appointment
Midatech Pharma Appointment
22
Mar
Mar
IFC Advisory advises on the Euro 128m sale of LSE listed Yew Grove REIT plc
IFC Advisory advises on the Euro 128m sale of LSE listed Yew Grove REIT plc, [...]
Feb
IFC Advisory advises on the sale of AIM listed Universe Group plc
IFC Advisory advises on the sale of AIM listed Universe Group plc, a leading developer [...]
Jan
Vector Capital appoint IFC Advisory
IFC Advisory appointed Financial PR adviser to AIM listed Vector Capital, the commercial lending group [...]
Jan